Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, July 18, 2023
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
[ Tue, Jul 18th 2023
] - WOPRAI
Paul Choi Maintained (BBIO) at Strong Buy with Increased Target to $50 on, Jul 18th, 2023
Paul Choi of Goldman Sachs, Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Increased Target from $29 to $50 on, Jul 18th, 2023.
Paul has made no other calls on BBIO in the last 4 months.
There are 3 other peers that have a rating on BBIO. Out of the 3 peers that are also analyzing BBIO, 0 agree with Paul's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Paul
- Salim Syed of "Mizuho" Maintained at Strong Buy with Increased Target to $29 on, Monday, May 8th, 2023
- Josh Schimmer of "Evercore ISI Group" Initiated at Buy and Held Target at $40 on, Wednesday, April 19th, 2023
- Mani Foroohar of "SVB Securities" Maintained at Buy with Increased Target to $27 on, Thursday, April 13th, 2023
